eferences:
1. The First Covid Vaccines May Not Prevent Covid Infection (1). 2020,
June 15. at
https://news.bloomberglaw.com/coronavirus/the-first-covid-vaccines-may-not-prevent-you-from-getting-covid?context=search&index=15&utm_source=twitter&campaign=B1BDE4E0-AF5C-11EA-A029-9CF94F017A06&utm_medium=lawdesk&fbclid=IwAR3HM9yKf4JxM99n0ZRqCd-QqFSn-WOcTc8T1NvOGnN1f-WaD3Ip0DCmBks.)
2. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of
Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. New England
Journal of Medicine 2020.
3. Fauci warns COVID-19 vaccine may be only partially effective, public
health measures still needed. 2020, August 7. at
https://www.reuters.com/article/us-health-coronavirus-fauci-vaccine/fauci-warns-covid-19-vaccine-may-be-only-partially-effective-public-health-measures-still-needed-idUSKCN2532YX.)
4. SARS CoV-2 adenovirus and RNA based vaccines potential autoimmune
complications: could we lower the chances? Authorea, 2020, November 30.
at
https://www.authorea.com/users/318758/articles/496102-sars-cov-2-adenovirus-and-rna-based-vaccines-potential-autoimmune-complications-could-we-lower-the-chances.)
5. Kelleni MT. Nitazoxanide/Azithromycin combination for COVID-19: A
suggested new protocol for COVID-19 early management. Pharmacological
Research 2020:104874.
6. 24 Studies found for: Nitazoxanide | Covid19. 2020, December
10. at
https://clinicaltrials.gov/ct2/results?cond=Covid19&term=Nitazoxanide&cntry=&state=&city=&dist=.)
7. Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 Therapy
with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in
Outpatient Settings Significantly Reduced Symptoms Compared to Known
Outcomes in Untreated Patients. medRxiv 2020:2020.10.31.20223883.
8. Ibuprofen potential addition to COVID-19 early management protocols:
could it be superior to paracetamol and hydroxychloroquine? 2020, May 6.
at
https://journal.sketchingscience.org/users/318758/articles/448656-ibuprofen-potential-addition-to-covid-19-early-management-protocols-could-it-be-superior-to-paracetamol-and-hydroxychloroquine.)
9. Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in
COVID-19 might reverse pathogenesis, prevent complications and improve
clinical outcomes. Biomedicine & Pharmacotherapy 2021;133:110982.
10. Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action.
Pediatric Anesthesia 2008;18:915-21.
11. Kelleni MT. ACEIs, ARBs, ibuprofen originally linked to COVID-19:
the other side of the mirror. Inflammopharmacology 2020.
12. Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does Ibuprofen
Worsen COVID-19? Drug safety 2020;43:611-4.
13. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use
and clinical outcomes in COVID-19 patients. Clinical Microbiology and
Infection.
14. Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and
mortality in users of non-steroidal anti-inflammatory drugs who tested
positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med
2020;17:e1003308.
15. Castro VM, Ross RA, McBride SMJ, Perlis RH. Identifying common
pharmacotherapies associated with reduced COVID-19 morbidity using
electronic health records. medRxiv 2020:2020.04.11.20061994.
16. Egypt COVID-19 TRACKER. 2020, December 10. at
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/egypt/.)
17. Remdesivir is least likely to be effective for safe treatment of
COVID-19: A pharmacovigilant point of view Authorea, 2020, December 01.
at www.authorea.com/496404/7jNIUYA0Nj7hHkx9PC6_lQ.)
18. Tan Q, Duan L, Ma Y, et al. Is oseltamivir suitable for fighting
against COVID-19: In silico assessment, in vitro and retrospective
study. Bioorg Chem 2020;104:104257-.
19. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for
COVID-19 –interim WHO SOLIDARITY trial results. medRxiv
2020:2020.10.15.20209817.
20. Horby PW, Mafham M, Bell JL, et al. Lopinavir-ritonavir in patients
admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled,
open-label, platform trial. The Lancet 2020;396:1345-52.
21. Tocilizumab, Remdesivir and Favipiravir repurposed for COVID-19: The
Good, The Bad and The Ugly. . Authorea, 2020, November 30.
22. Hu H-R. Fatal Vitamin K-Dependent Coagulopathy Associated with
Cefoperazone/Sulbactam: A Case Report. Drug Saf Case Rep 2019;6:6-.
23. Coronavirus: Virus isolation period extended from seven to 10 days.
2020, July 30. at https://www.bbc.com/news/uk-53588709.)
24. Li M, Chen P, Yuan Q, Song B, Ma J. Transmission characteristics of
the COVID-19 outbreak in China: a study driven by data. medRxiv
2020:2020.02.26.20028431.
25. Breakthrough: Ibuprofen/nitazoxanide/azithromycin: a battle changer
personalized COVID-19 telemedicine five days protocol. 2020, June 22. at
https://www.authorea.com/users/318758/articles/460853-breakthrough-ibuprofen-nitazoxanide-azithromycin-a-battle-changer-personalized-covid-19-telemedicine-five-days-protocol?commit=52337e49b98b96fae21dab166828780e5f544a80.)
26. Hong W, Chen Y, You K, et al. Celebrex Adjuvant Therapy on
Coronavirus Disease 2019: An Experimental Study. Frontiers in
Pharmacology 2020;11.